Kazuto Nishio

发表

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

S. Tomida, J. Tanizaki, R. Hatae, 2024, The Journal of clinical investigation.

Downregulated expression of PBRM1 in sarcomatoid hepatocellular carcinoma

M. D. De Velasco, K. Sakai, Shogo Tanaka, 2024, Oncology letters.

TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer

K. Sakai, M. Kai, Mai Yamada, 2024, Cancers.

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma

T. Ohira, Y. Miyata, M. Takeda, 2024, JTO clinical and research reports.

Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

J. Tanizaki, K. Sakai, H. Hayashi, 2024, British Journal of Cancer.

Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer

K. Akakura, S. Sakamoto, N. Anzai, 2024, AntiCancer Research.

A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk.

M. D. De Velasco, M. Matsushita, Y. Kura, 2024, The Prostate.

Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer.

M. D. De Velasco, Y. Kura, K. Sakai, 2024, Human cell.

A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin.

M. D. De Velasco, Y. Kura, K. Sakai, 2024, International journal of clinical oncology.